Cargando…

Behavioral Effects of a Novel Benzofuranyl-Piperazine Serotonin-2C Receptor Agonist Suggest a Potential Therapeutic Application in the Treatment of Obsessive–Compulsive Disorder

Selective serotonin reuptake inhibitors (SSRIs) are the only effective pharmacological treatments for obsessive–compulsive disorder (OCD). Nonetheless, their generally limited efficacy, side-effects, and delayed onset of action require improved medications for this highly prevalent disorder. Preclin...

Descripción completa

Detalles Bibliográficos
Autores principales: Rodriguez, Michelle M., Overshiner, Carl, Leander, J. David, Li, Xia, Morrow, Denise, Conway, Richard G., Nelson, David L., Briner, Karin, Witkin, Jeffrey M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5438973/
https://www.ncbi.nlm.nih.gov/pubmed/28588509
http://dx.doi.org/10.3389/fpsyt.2017.00089
_version_ 1783237859575070720
author Rodriguez, Michelle M.
Overshiner, Carl
Leander, J. David
Li, Xia
Morrow, Denise
Conway, Richard G.
Nelson, David L.
Briner, Karin
Witkin, Jeffrey M.
author_facet Rodriguez, Michelle M.
Overshiner, Carl
Leander, J. David
Li, Xia
Morrow, Denise
Conway, Richard G.
Nelson, David L.
Briner, Karin
Witkin, Jeffrey M.
author_sort Rodriguez, Michelle M.
collection PubMed
description Selective serotonin reuptake inhibitors (SSRIs) are the only effective pharmacological treatments for obsessive–compulsive disorder (OCD). Nonetheless, their generally limited efficacy, side-effects, and delayed onset of action require improved medications for this highly prevalent disorder. Preclinical and clinical findings have suggested serotonin2C (5-HT(2C)) receptors as a potential drug target. Data in rats and mice are presented here on the effects of a novel 5-HT(2C) receptor agonist ((3S)-3-Methyl-1-[4-(trifluoromethyl)-7-benzofuranyl]-piperazine) (CPD 1) with high potency and full efficacy at 5-HT(2C) receptors and less potency and partial agonism at 5-HT(2A) and 5-HT(2B) receptors. Effects of CPD 1 on consummatory (schedule-induced polydipsia in rats) and non-consummatory behaviors (marble-burying and nestlet-shredding in mice) that are repetitive and non-habituating were studied. We also evaluated the effects of CPD 1 in rats with isoproterenol- and deprivation-induced drinking in rats to compare with the polydipsia studies. The SSRIs, fluoxetine, and chlomipramine decreased the high rates of drinking in rats engendered by a schedule of intermittent food delivery (schedule-induced polydipsia). The effects of fluoxetine, but not of d-amphetamine, were prevented by the selective 5-HT(2C) receptor antagonist SB242084. The 5-HT(2C) receptor agonists Ro 60-0175 and CPD 1 also decreased drinking, but unlike the SSRIs and Ro 60-0175, CPD 1 dose-dependently decreased excessive drinking without affecting lever press responses that produced food. The effects of CPD 1 were prevented by SB242084. CPD 1 also suppressed drinking induced by isoproterenol and by water deprivation without affecting normative drinking behavior. CPD 1, like fluoxetine, also suppressed marble-burying and nestlet-shredding in mice at doses that did not affect rotarod performance or locomotor activity. The behavioral specificity of effects of CPD 1 against repetitive and excessive behaviors suggests a potential therapeutic application in OCD.
format Online
Article
Text
id pubmed-5438973
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-54389732017-06-06 Behavioral Effects of a Novel Benzofuranyl-Piperazine Serotonin-2C Receptor Agonist Suggest a Potential Therapeutic Application in the Treatment of Obsessive–Compulsive Disorder Rodriguez, Michelle M. Overshiner, Carl Leander, J. David Li, Xia Morrow, Denise Conway, Richard G. Nelson, David L. Briner, Karin Witkin, Jeffrey M. Front Psychiatry Psychiatry Selective serotonin reuptake inhibitors (SSRIs) are the only effective pharmacological treatments for obsessive–compulsive disorder (OCD). Nonetheless, their generally limited efficacy, side-effects, and delayed onset of action require improved medications for this highly prevalent disorder. Preclinical and clinical findings have suggested serotonin2C (5-HT(2C)) receptors as a potential drug target. Data in rats and mice are presented here on the effects of a novel 5-HT(2C) receptor agonist ((3S)-3-Methyl-1-[4-(trifluoromethyl)-7-benzofuranyl]-piperazine) (CPD 1) with high potency and full efficacy at 5-HT(2C) receptors and less potency and partial agonism at 5-HT(2A) and 5-HT(2B) receptors. Effects of CPD 1 on consummatory (schedule-induced polydipsia in rats) and non-consummatory behaviors (marble-burying and nestlet-shredding in mice) that are repetitive and non-habituating were studied. We also evaluated the effects of CPD 1 in rats with isoproterenol- and deprivation-induced drinking in rats to compare with the polydipsia studies. The SSRIs, fluoxetine, and chlomipramine decreased the high rates of drinking in rats engendered by a schedule of intermittent food delivery (schedule-induced polydipsia). The effects of fluoxetine, but not of d-amphetamine, were prevented by the selective 5-HT(2C) receptor antagonist SB242084. The 5-HT(2C) receptor agonists Ro 60-0175 and CPD 1 also decreased drinking, but unlike the SSRIs and Ro 60-0175, CPD 1 dose-dependently decreased excessive drinking without affecting lever press responses that produced food. The effects of CPD 1 were prevented by SB242084. CPD 1 also suppressed drinking induced by isoproterenol and by water deprivation without affecting normative drinking behavior. CPD 1, like fluoxetine, also suppressed marble-burying and nestlet-shredding in mice at doses that did not affect rotarod performance or locomotor activity. The behavioral specificity of effects of CPD 1 against repetitive and excessive behaviors suggests a potential therapeutic application in OCD. Frontiers Media S.A. 2017-05-22 /pmc/articles/PMC5438973/ /pubmed/28588509 http://dx.doi.org/10.3389/fpsyt.2017.00089 Text en Copyright © 2017 Rodriguez, Overshiner, Leander, Li, Morrow, Conway, Nelson, Briner and Witkin. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Psychiatry
Rodriguez, Michelle M.
Overshiner, Carl
Leander, J. David
Li, Xia
Morrow, Denise
Conway, Richard G.
Nelson, David L.
Briner, Karin
Witkin, Jeffrey M.
Behavioral Effects of a Novel Benzofuranyl-Piperazine Serotonin-2C Receptor Agonist Suggest a Potential Therapeutic Application in the Treatment of Obsessive–Compulsive Disorder
title Behavioral Effects of a Novel Benzofuranyl-Piperazine Serotonin-2C Receptor Agonist Suggest a Potential Therapeutic Application in the Treatment of Obsessive–Compulsive Disorder
title_full Behavioral Effects of a Novel Benzofuranyl-Piperazine Serotonin-2C Receptor Agonist Suggest a Potential Therapeutic Application in the Treatment of Obsessive–Compulsive Disorder
title_fullStr Behavioral Effects of a Novel Benzofuranyl-Piperazine Serotonin-2C Receptor Agonist Suggest a Potential Therapeutic Application in the Treatment of Obsessive–Compulsive Disorder
title_full_unstemmed Behavioral Effects of a Novel Benzofuranyl-Piperazine Serotonin-2C Receptor Agonist Suggest a Potential Therapeutic Application in the Treatment of Obsessive–Compulsive Disorder
title_short Behavioral Effects of a Novel Benzofuranyl-Piperazine Serotonin-2C Receptor Agonist Suggest a Potential Therapeutic Application in the Treatment of Obsessive–Compulsive Disorder
title_sort behavioral effects of a novel benzofuranyl-piperazine serotonin-2c receptor agonist suggest a potential therapeutic application in the treatment of obsessive–compulsive disorder
topic Psychiatry
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5438973/
https://www.ncbi.nlm.nih.gov/pubmed/28588509
http://dx.doi.org/10.3389/fpsyt.2017.00089
work_keys_str_mv AT rodriguezmichellem behavioraleffectsofanovelbenzofuranylpiperazineserotonin2creceptoragonistsuggestapotentialtherapeuticapplicationinthetreatmentofobsessivecompulsivedisorder
AT overshinercarl behavioraleffectsofanovelbenzofuranylpiperazineserotonin2creceptoragonistsuggestapotentialtherapeuticapplicationinthetreatmentofobsessivecompulsivedisorder
AT leanderjdavid behavioraleffectsofanovelbenzofuranylpiperazineserotonin2creceptoragonistsuggestapotentialtherapeuticapplicationinthetreatmentofobsessivecompulsivedisorder
AT lixia behavioraleffectsofanovelbenzofuranylpiperazineserotonin2creceptoragonistsuggestapotentialtherapeuticapplicationinthetreatmentofobsessivecompulsivedisorder
AT morrowdenise behavioraleffectsofanovelbenzofuranylpiperazineserotonin2creceptoragonistsuggestapotentialtherapeuticapplicationinthetreatmentofobsessivecompulsivedisorder
AT conwayrichardg behavioraleffectsofanovelbenzofuranylpiperazineserotonin2creceptoragonistsuggestapotentialtherapeuticapplicationinthetreatmentofobsessivecompulsivedisorder
AT nelsondavidl behavioraleffectsofanovelbenzofuranylpiperazineserotonin2creceptoragonistsuggestapotentialtherapeuticapplicationinthetreatmentofobsessivecompulsivedisorder
AT brinerkarin behavioraleffectsofanovelbenzofuranylpiperazineserotonin2creceptoragonistsuggestapotentialtherapeuticapplicationinthetreatmentofobsessivecompulsivedisorder
AT witkinjeffreym behavioraleffectsofanovelbenzofuranylpiperazineserotonin2creceptoragonistsuggestapotentialtherapeuticapplicationinthetreatmentofobsessivecompulsivedisorder